Nov 22, 2021 9:25am EST LIXTE BIOTECHNOLOGY HOLDINGS, INC. ANNOUNCES THAT ENROLLMENT HAS RESUMED IN NATIONAL CANCER INSTITUTE’S TRIAL TO DETERMINE ABILITY OF LIXTE COMPOUND LB-100 TO ENTER RECURRENT, MALIGNANT BRAIN TUMORS
Oct 20, 2021 9:25am EDT Lixte Biotechnology to Discuss its Collaboration with Leading European Cancer Centers at the Benzinga Global Small Cap Conference on October 28
